Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer

Cancer

Volumn 115, Issue 11, 2009, Pages 2388-2399

  Taylor, Lockwood G ^a   Canfield, Steven E ^b   Du, Xianglin L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Androgen deprivation therapy; Cardiovascular disease; Fracture; Osteoporosis; Prostate cancer; Side effects

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; VITAMIN D;

ANDROGEN DEPRIVATION THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; FRACTURE; GENETIC HETEROGENEITY; HUMAN; MALE; OSTEOPENIA; OSTEOPOROSIS; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SURVIVAL; SYMPTOMATOLOGY;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 66649136169     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24283     Document Type: Review

References (53)

1. American Cancer Society. Overview: Prostate Cancer. Available at: http://www.cancer.org Accessed June 7, 2008.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
3. Damber J, Aus G. Prostate cancer. Lancet. 2008;371:1710-1721.
4. Baade PD, Coory MD, Aitken JF. International trends in prostate-cancer mortality: the decrease in continuing and spreading. Cancer Causes Control. 2004;15:237-241. (Pubitemid 38988032)
5. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238-244. (Pubitemid 41043794)
6. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295-300. (Pubitemid 27318990)
7. Chodak GW, Keane T, Klotz L; the Hormone Therapy Study Group. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology. 2002;60:201-208.
8. Shahinian VB, Kuo Y, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615-1624. (Pubitemid 40490022)
9. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95:918-999. (Pubitemid 36896715)
10. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol. 1997;79:235-246. (Pubitemid 127798053)
11. Huggins C, Hodges CV. Studies on prostatic cancer, I: the effect of estrogen and of androgen injection on serum phosphates in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
12. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002;360:103-108. (Pubitemid 34786197)
13. Damber JE. Decreasing mortality rates for prostate cancer: possible role of hormonal therapy? BJU Int. 2004;93:695-701.
14. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300:173-181.
15. Holmes L, Chan W, Jiang Z, Du XL. Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer. Prostate Cancer Prostatic Dis. 2007;10:388-395. (Pubitemid 350238090)
16. Green HJ, Pakenham KI, Headley BC, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int. 2004;93:975-979. (Pubitemid 38758617)
17. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166:465-471.
18. Famili P, Cauley JA, Greenspan SL. The effect of androgen deprivation therapy on periodontal disease in men with prostate cancer. J Urol. 2007;177:921-924. (Pubitemid 46223569)
19. Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR. Estrogenic side effects of androgen deprivation therapy. Rev Urol. 2007;9:163-180.
20. Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006;60:201-215. (Pubitemid 44709617)
21. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrin Metab. 2008;93:2042-2049.
22. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57:127-132. (Pubitemid 32065833)
23. Preston DM, Torrens JI, Harding P, Howard RS, Duncan WE, Mcleod DG. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis. 2002;5:304-310. (Pubitemid 36124442)
24. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305-1308.
25. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106:581-588. (Pubitemid 43157621)
26. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S. Lipoprofile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res. 2006;18:494-498. (Pubitemid 44330303)
27. Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol. 2006;176:520-525. (Pubitemid 43927931)
28. Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int. 2005;16:707-711. (Pubitemid 40897469)
29. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;13:154-164. (Pubitemid 40096612)
30. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897-7903. (Pubitemid 46657388)
31. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175:136-139. (Pubitemid 41797111)
32. Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int. 2007;100:749-754. (Pubitemid 47360203)
33. Morote J, Morin JP, Orsola A, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69:500-504. (Pubitemid 46428384)
34. Morote J, Martinez E, Trilla E, et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol. 2003;44:661-665. (Pubitemid 37542923)
35. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90:6410-6417. (Pubitemid 41759293)
36. Keating NL, O'Malley J, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448-4456. (Pubitemid 46630983)
37. Lage MJ, Barber BL, Markus RA. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology. 2007;70:1104-1108. (Pubitemid 350297379)
38. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493-1500. (Pubitemid 47463063)
39. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516-1524.
40. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol. 2008;54:816-823.
41. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420-2425. (Pubitemid 46999213)
42. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948-955.
43. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008-2012. (Pubitemid 36576705)
44. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zolendronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176:972-978. (Pubitemid 44142571)
45. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract. 2008;5:24-34.
46. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146:416-424.
47. Saad F. Clinical benefit of zolendronic acid for the prevention of skeletal complication in advanced prostate cancer. Clin Prostate Cancer. 2005;4:31-37. (Pubitemid 41018180)
48. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing longterm androgen-deprivation therapy. J Clin Oncol. 2006;24:3979-3983. (Pubitemid 46630747)
49. Haidar A, Yassin A, Saad F, Shabsigh R. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male. 2007;10:189-196. (Pubitemid 350146723)
50. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer. Arch Intern Med. 2007;167:612-613. (Pubitemid 46513232)
51. Hsing AW, Chua S, Gao YT, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst. 2001;93:783-789. (Pubitemid 32514802)
52. Hsing AW, Gao YT, Chua S, Deng J, Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst. 2003;95:67-71. (Pubitemid 36124297)
53. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomizes trial. JAMA. 2008;299:289-295.